Orion Corporation (Finland)

Recent papers from Orion Corporation (Finland)

1. Fifty Years of Non-Adrenergic Inotropes in Heart FailureJournal of Cardiovascular Pharmacology · 2026
2. Burden of attention deficit hyperactivity disorder (ADHD) on people and society in Finland – a nationwide register study in 2015–2021BMC Psychiatry · 2026
3. Study on the Pharmacokinetics and Pharmacodynamics of Transdermal Estradiol Gel Administered Repeatedly in Postmenopausal WomenDrugs in R&D · 2026
4. Concurrent Use of Tasipimidine Oral Solution and Fluoxetine in DogsJournal of Veterinary Pharmacology and Therapeutics · 2026
5. The reduction potential of diet board feeding—survival and clinical chemistry of group-housed Sprague Dawley rats in a 24-month studyLaboratory Animals · 2026
6. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialEuropean Journal of Cancer · 2026
7. Precision tumor-on-chip for personalized assessment of drug efficacy and immune cell deliveryCell Reports Methods · 2026
8. OMAHA-004: Phase 3 trial of the steroidogenesis inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.Journal of Clinical Oncology · 2026
9. Phase 1/2 OMAHA-U01 substudy 01A: Oral steroidogenesis inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
10. First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).Journal of Clinical Oncology · 2026
11. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failureEuropean Heart Journal · 2012
12. Burden of Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Adults: Significant Adverse Outcomes and Costs beyond Direct TreatmentInfectious Diseases and Therapy · 2026
13. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failureJournal of the American College of Cardiology · 2000
14. Catalytic Amidation of Carboxylic Acids Using ortho -Aminophenylboronic AcidsACS Organic & Inorganic Au · 2026
15. Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectorsTyöväentutkimus Vuosikirja · 2026
16. Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A)Journal of Molecular Medicine · 2026
17. Mapping the Extended Pain Pathway: Human Genetic and Multi-Omic Strategies for Next-Generation AnalgesicsInternational Journal of Molecular Sciences · 2026
18. Transcriptomic and proteomic insights into progressive myoclonus epilepsy, EPM1Disease Models & Mechanisms · 2026
19. α-Lactose monohydrate – new insights into physicochemical response to temperature and humidity exposureInternational Journal of Pharmaceutics · 2026
20. OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy.Journal of Clinical Oncology · 2026